ConductScience.org, home

Paper41345477

LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma.

Zhang J and 11 others. Sci Rep, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma. Papers, record 41345477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345477

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
LIMD2 is associated with an exhausted CD8⁺ T cell state linked to ICI response in clear cell renal cell carcinoma.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-26
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang JJunfeng
2Peng QQingyan
3Xiang XXiaolong
4Liu FFuzhong
5Jiang XXiangdong
6Nie HHongwei
7Bi XXing
8Pan TTing
9Li KKailing
10Chen PPeng
11Yuan SShuai
12Chen SSu

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Renal CellMajor topic
CD8-Positive T-LymphocytesMajor topic
Kidney NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
LIM Domain ProteinsMajor topic
Humans
Lymphocytes, Tumor-Infiltrating
Single-Cell Analysis
Gene Expression Regulation, Neoplastic
Male

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82260791National Natural Science Foundation of ChinaPubMed
32560174National Natural Science Foundation of ChinaPubMed
2025AFD770Natural Science Foundation of Hubei ProvincialPubMed
2024E02058Science and Technology Assistance Program for XinjiangPubMed
2023D01C124Natural Science Foundation of Xinjiang Uygur Autonomous RegionPubMed

Source PubMed

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
225348003Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.Nat Commun2014https://conductscience.org/library/papers/25348003PubMed
324590809LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.Cancer Res2014https://conductscience.org/library/papers/24590809PubMed
427538576Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.Cancer Immunol Res2016https://conductscience.org/library/papers/27538576PubMed
533711273Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.Cancer Cell2021https://conductscience.org/library/papers/33711273PubMed
634354714CD8+ T Cell Exhaustion in Cancer.Front Immunol2021https://conductscience.org/library/papers/34354714PubMed
731031094Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.Cell Metab2019https://conductscience.org/library/papers/31031094PubMed
834580473Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.Nat Rev Clin Oncol2022https://conductscience.org/library/papers/34580473PubMed
933711272Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.Cancer Cell2021https://conductscience.org/library/papers/33711272PubMed
1027570942Radiotherapy combination opportunities leveraging immunity for the next oncology practice.CA Cancer J Clin2017https://conductscience.org/library/papers/27570942PubMed
1134597799ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.Ann Oncol2021https://conductscience.org/library/papers/34597799PubMed
1236793322Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy.Mater Today Bio2023https://conductscience.org/library/papers/36793322PubMed
1334715028Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.Cancer Cell2021https://conductscience.org/library/papers/34715028PubMed
1430096699Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences.Cancer Treat Rev2018https://conductscience.org/library/papers/30096699PubMed
1533658305Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.J Immunother Cancer2021https://conductscience.org/library/papers/33658305PubMed
1631591533Precursor exhausted T cells: key to successful immunotherapy?Nat Rev Immunol2020https://conductscience.org/library/papers/31591533PubMed
1732951909Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?J Hepatol2020https://conductscience.org/library/papers/32951909PubMed
1830676822CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.Annu Rev Immunol2019https://conductscience.org/library/papers/30676822PubMed
1938854736
Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group.
Front Oncol2024https://conductscience.org/library/papers/38854736PubMed
2025809635PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.Nat Commun2015https://conductscience.org/library/papers/25809635PubMed

See all 49 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
LIMD280774PubTator's text mininghttps://conductscience.org/library/genes/80774NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41345477

GET https://conductscience.org/api/papers/v1/41345477/references?page=2